Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies - Episode 9

PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors

,

The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.

  1. PostMONARCH Subgroup data in ESR1 and PIK3CA